Carey-Fineman-Ziter syndrome (CFZS) is a rare inherited muscle disorder caused by mutations in the MYMK gene, which provides instructions for a protein called Myomaker that muscle cells need to fuse together during development. Children born with CFZS typically have facial weakness, a small jaw, and low muscle tone from birth, along with a variable collection of other features that can affect the eyes, spine, and other organ systems. Because so few cases have been identified worldwide, the syndrome was poorly understood for decades after its initial description, and the genetic cause was only pinpointed in 2017.
The Genetic Cause
CFZS follows an autosomal recessive inheritance pattern, meaning a child must inherit a faulty copy of the MYMK gene from each parent to develop the condition. Carriers who have only one altered copy are unaffected. The mutations identified so far are missense changes, meaning they swap one building block in the protein for another rather than deleting large stretches of the gene. Researchers identified compound heterozygous or homozygous MYMK missense mutations in affected members of four sibling pairs and one individual case, confirming that MYMK was the only gene harboring recessive variants common to all families studied.1Nature Communications. A defect in myoblast fusion underlies Carey-Fineman-Ziter syndrome
A critical detail is that these mutations reduce Myomaker’s function without completely destroying it.2PubMed Central. A defect in myoblast fusion underlies Carey-Fineman-Ziter syndrome Complete loss of Myomaker in animal models is lethal because skeletal muscle cannot form at all. In CFZS, enough residual function remains for muscle to develop, but the process is impaired enough to cause the constellation of problems seen in affected individuals.
What Myomaker Does and Why It Matters
Skeletal muscle forms when individual precursor cells called myoblasts fuse together into long, multinucleated fibers. Myomaker is a membrane protein found specifically on skeletal muscle cells, and it is essential for this fusion step.3PubMed. Cryo-EM structures of Myomaker reveal a molecular basis for myoblast fusion Think of it as the molecular handshake that lets two muscle precursor cells recognize each other and merge their membranes. When Myomaker is partially defective, fewer cells fuse successfully, and the muscle fibers that do form are structurally abnormal.
This mechanism explains why CFZS affects so many different parts of the body. Muscle is everywhere, and different muscle groups develop at slightly different times during fetal life. The facial muscles that control expression and eye movement, the muscles of the jaw and palate, the muscles supporting the spine, and the muscles of the limbs are all downstream targets of impaired myoblast fusion. The syndrome’s seemingly unrelated features, from a small jaw to weak eye muscles to floppy tone, all trace back to the same root problem.
Clinical Features
The three hallmark features present in nearly every reported case are facial weakness resembling Möbius sequence, a small or receding jaw (sometimes accompanied by cleft palate as part of Pierre Robin sequence), and generalized low muscle tone from birth.4American Journal of Medical Genetics. Mbius sequence, Robin complex, and hypotonia: Severe expression of brainstem disruption spectrum versus Carey-Fineman-Ziter syndrome Beyond this core triad, the clinical picture varies considerably from person to person. Additional features reported in affected children include developmental delay, hydronephrosis (swelling of a kidney due to urine backup), and bilateral clubfeet.5PubMed. Pontine hypoplasia in Carey-Fineman-Ziter (CFZ) syndrome
The variability across patients is well documented. When researchers scored the presence or absence of up to 19 clinical and 4 laboratory features in a group of confirmed cases, individual scores ranged from 68% to 96%, meaning no two patients had an identical set of features.1Nature Communications. A defect in myoblast fusion underlies Carey-Fineman-Ziter syndrome This variability likely reflects how much residual Myomaker function each person’s specific mutations allow, combined with other genetic and developmental factors that modify the outcome.
The facial weakness in CFZS deserves special attention because it often dominates early clinical impressions. Affected infants may have a mask-like face with limited ability to smile, close the eyes fully, or move the lips normally. Feeding difficulties are common in the newborn period, partly because of the weak facial muscles and partly because of the small jaw and cleft palate when present. Breathing problems can also arise early, particularly if the airway is compromised by the combination of a tiny jaw and poor muscle tone.
A Surprising Muscle Biopsy Finding
When doctors take a small sample of muscle tissue from a child with CFZS and examine it under a microscope, the result is counterintuitive. Rather than seeing small, wasted muscle fibers as you might expect in a condition that causes weakness and low tone, biopsies reveal markedly enlarged fibers. Both major fiber types are affected, with diameters more than twice that of age-matched healthy children.6PubMed Central. Carey-Fineman-Ziter syndrome with mutations in the myomaker gene and muscle fiber hypertrophy
This finding is unusual among congenital muscle diseases, where fiber smallness or structural disarray is far more common. The leading explanation is that when fewer myoblasts fuse during development, the fibers that do form compensate by growing larger. The total number of muscle fibers is likely reduced, and each surviving fiber hypertrophies to partially fill the gap. Despite their large size, these fibers do not produce normal strength, which is why affected individuals remain weak and hypotonic. This distinctive biopsy pattern can actually help point clinicians toward CFZS when the genetic diagnosis has not yet been made.
How CFZS Is Distinguished from Similar Conditions
Several other rare syndromes share enough features with CFZS to create diagnostic confusion, and sorting them out matters because each has different implications for management and genetic counseling.
The most commonly confused condition is Moebius syndrome, which also involves facial weakness and eye movement problems. A useful clinical distinction is that people with CFZS can usually move their eyes outward (abduct them) almost fully, whereas in classic Moebius syndrome that outward movement is severely limited or absent.7Nature Communications. A defect in myoblast fusion underlies Carey-Fineman-Ziter syndrome – Section: Discussion This difference reflects the fact that CFZS is fundamentally a muscle disease, not a cranial nerve problem. The facial weakness in CFZS comes from defective muscle development, while in Moebius syndrome it stems from underdevelopment of the cranial nerves that supply those muscles.
Native American myopathy, caused by mutations in a different gene called STAC3, is another condition with significant clinical overlap. It shares the combination of facial and generalized weakness, relatively normal eye movements, low tone, cleft palate, and scoliosis. A key distinguishing feature is that Native American myopathy carries a risk of malignant hyperthermia, a dangerous reaction to certain anesthetics, which has not been reported in CFZS.8PubMed Central. Identification of STAC3 variants in non-Native American families with overlapping features of Carey-Fineman-Ziter syndrome and Moebius syndrome This distinction has real consequences in the operating room, because children with either condition often need surgery for cleft palate repair, spinal correction, or other interventions.
Researchers have also noted overlap with EMARDD, a condition caused by MEGF10 mutations that features early-onset muscle weakness, absent reflexes, breathing difficulty, and swallowing problems. CFZS may be most similar to EMARDD in terms of how the underlying biology works, since both involve defects in the process by which muscle precursor cells multiply and fuse. Yet other conditions in the differential include SEPN1-related myopathy, which shares the pattern of fatty infiltration seen on muscle imaging in CFZS but typically does not produce prominent facial weakness.7Nature Communications. A defect in myoblast fusion underlies Carey-Fineman-Ziter syndrome – Section: Discussion
Genetic testing for MYMK mutations has made diagnosis far more straightforward than it was before 2017, when clinicians had to rely entirely on the pattern of clinical features to distinguish CFZS from these overlapping syndromes. For families who received a clinical diagnosis of CFZS in earlier years, confirmatory genetic testing is now available and can provide a definitive answer.
Scoliosis and Its Management
Scoliosis is one of the more common and practically significant complications in CFZS. The combination of generalized muscle weakness and abnormal muscle fiber development means the spine lacks the muscular support needed to grow straight, and curvature tends to progress through childhood and especially during the pubertal growth spurt.
A detailed case report illustrates the typical trajectory. Scoliosis was first noticed by a patient’s parents at age four. By the time she was evaluated at a specialty clinic near age nine, she had a right thoracic curve measuring 54 degrees with a compensatory left lumbar curve of 28 degrees. Bracing was started to delay surgery and allow more growth, and the patient tolerated a custom-molded brace until age twelve. During her rapid pubertal growth spurt, the primary curve progressed to 81 degrees despite the brace, advancing at roughly 8 degrees per year. The curve had become rigid, and she ultimately underwent posterior spinal fusion spanning most of her thoracic and lumbar spine. Five years after surgery, she had returned to her normal activities with the hardware in good position and no loss of correction.9The Central European Journal of Paediatrics. Scoliosis in Carey-Fineman-Ziter Syndrome: Clinical Course, Association with Pierre Robin Sequence and Treatment
This case captures several practical lessons. Bracing can buy time but may not prevent surgical correction in a child whose underlying muscle weakness fuels relentless curve progression. Timing surgery to allow enough spinal growth while avoiding a curve so severe that it compromises lung function is a balancing act. And because children with CFZS may also have breathing difficulties related to their muscle weakness, preoperative respiratory evaluation is especially important. The anesthesia team also needs to be aware that CFZS can look similar to conditions carrying malignant hyperthermia risk, even though CFZS itself has not been associated with that complication.
Living with CFZS
Because CFZS affects so many body systems, care typically involves a team of specialists. Newborns may need help with feeding, whether through specialized bottles, nasogastric tubes, or positioning techniques that accommodate the small jaw. Cleft palate repair, if needed, usually happens in the first year or two of life. Ophthalmology follow-up tracks eye movement and helps manage any vision issues related to incomplete eye closure or limited gaze. Physical and occupational therapy are mainstays throughout childhood, aimed at maximizing strength, mobility, and functional independence despite the underlying muscle impairment.
Developmental delay, reported in some but not all cases, varies in severity. Some children reach milestones slowly but eventually achieve typical cognitive function, while others need ongoing educational support. The facial weakness can have social and emotional implications that are easy to underestimate. A child who cannot smile has a harder time signaling friendliness and engagement to peers, and families sometimes find that this aspect of the condition affects daily life as much as the physical limitations do.
Respiratory monitoring is relevant throughout life. The same muscle weakness that causes generalized hypotonia also affects the muscles of breathing, and some individuals develop restrictive lung disease, especially if scoliosis narrows the chest cavity. Sleep studies may be recommended to check for nighttime breathing problems, and respiratory support ranging from noninvasive ventilation to more intensive measures can become necessary in more severely affected individuals.
Myomaker Research Beyond CFZS
The discovery that Myomaker is the key protein behind CFZS opened a door that extends well beyond this rare syndrome. Understanding how muscle cells fuse has implications for muscle diseases that are far more common, such as Duchenne muscular dystrophy. In a striking example, researchers engineered viruses to carry Myomaker and its partner protein Myomerger on their outer membranes, creating a delivery system that specifically targets skeletal muscle. When these engineered viruses were loaded with a miniaturized version of the dystrophin gene and injected into mice with a form of muscular dystrophy, the mice produced dystrophin protein months later, showing improved muscle membrane stability and partial recovery of muscle strength.10Cell Press. Muscle fusogens go viral for gene delivery to skeletal muscle
The idea is elegant: the same molecular machinery that, when broken, causes CFZS can be harnessed to solve a major problem in gene therapy, which is getting therapeutic genes into muscle tissue efficiently and specifically. Conventional gene therapy vectors do not preferentially target muscle, so high doses are needed and off-target effects in the liver and other organs are a concern. A delivery system that uses muscle-specific fusion proteins to enter only muscle cells could dramatically improve the safety and efficiency of gene therapies for conditions like Duchenne, limb-girdle muscular dystrophies, and potentially even age-related muscle loss.
For families affected by CFZS itself, gene therapy is not yet on the horizon as a treatment, since the syndrome involves developmental events that occurred before birth and cannot be easily reversed after the fact. But the broader research attention that MYMK and Myomaker are now receiving means the biology of this pathway is being investigated with an intensity that would have been unimaginable when the syndrome was first described. That deeper understanding may eventually lead to therapeutic strategies, even if they look different from conventional gene replacement, by finding ways to boost the residual fusion capacity that CFZS patients retain.